THU0419 Rapid3 Performs Well Identifying Treatment Effect in The Tight Control of Psoriatic Arthritis Study

BackgroundRAPID3 is a patient completed outcome measure assessing disease activity in inflammatory arthritis consisting of the health assessment questionnaire (HAQ) and two VAS scales. It is feasible for use in clinical practice and has been well validated in rheumatoid arthritis (RA) and other conditions, but there is little data on its use in psoriatic arthritis (PsA).ObjectivesTo investigate the responsiveness and discrimination of RAPID3 and a modified version with skin VAS in the Tight Control of Psoriatic Arthritis (TICOPA) trial.MethodsData from the TICOPA trial were used to assess the performance of the RAPID3 index. RAPID3 was calculated using the HAQ-DI, patient completed pain VAS and global disease activity VAS. Due to concerns about skin involvement in PsA, we also calculated a novel RAPID3Ps score which also included a skin activity VAS to see if performance was superior.Results from the RAPID3 measures were correlated with the PsA disease activity score (PASDAS) a composite disease activity score already validated by GRAPPA. Change in the RAPID3 measures and other outcome measures were compared between the tight control arm and the standard care arm of the TICOPA study using t-test for continuous variables and chi-squared for categorical measures of disease state.ResultsRAPID3 scores strongly correlated with PASDAS (Pearson correlation 0.794, p